Secondary prevention of meningococcal disease

BMJ

Volumn 312, Issue 7031, 1996, Pages 591-592

  Kristiansen, Bjorn Erik ^a   Knapskog, Arne Birger ^a  

^a Telemark Biomedical Centre   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PENICILLIN G; RIFAMPICIN;

ANTIBIOTIC PROPHYLAXIS; EDITORIAL; HIGH RISK POPULATION; HUMAN; MENINGOCOCCOSIS; PRIORITY JOURNAL; SECONDARY PREVENTION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HUMANS; MENINGITIS, MENINGOCOCCAL; PENICILLINS; RIFAMPIN; RISK FACTORS;

EID: 0029987093     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.312.7031.591     Document Type: Editorial

References (12)

1. Kristiansen BE, Tveten Y, Ask E, Reiten T, Knapskog A-B, Steen-Johnsen J, et al. Preventing secondary cases of meningococcal disease by identifying and eradicating disease-causing strains in close contacts of patients. Scand J Infect Dis 1992; 24: 165–173.
2. Reller LB, McGregor RR, Beaty HN. Bactericidal antibody after colonization with Neisseria meningitidis. J Infect Dis 1973; 127: 56–62.
3. Hiby EA, Moe PJ, Lystad A, Frholm LO. Phenoxymethylpenicillin treatment of household contacts of meningococcal disease patients. Antonie van Leeuwenhoek 1986; 52: 255–257.
4. Begg N. Outbreak management. In: CartwrightK, ed. Meningococcal disease. Chichester: John Wiley, 1995: 285–307.
5. Yagupsky P, Ashkenazi S, Block C. Rifampicin-resistant meningococci causing invasive disease and failure of chemoprophylaxis. Lancet 1993; 341: 1152–3.
6. Jones DM. Control of meningococcal disease ditorial. BMJ 1989; 298: 542–543.
7. Benenson AS, ed. Control of communicable diseases manual. Washington DC: American Public Health Association, 1995.
8. Gilja OH, Halstensen A, Digranes A, Mylvaganam H, Aksnes A, Hiby EA. Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis. Antimicrob Agents Chemother 1993; 37: 2024–6.
9. Twumasi PA Jr, Kumah S, Leach A, O'Dempsey JD, Ceesay SJ, Todd J, et al. A trial of group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995; 171: 632–638.
10. Frasch CE. Meningococcal vaccines: past, present and future. In: CartwrightK, ed. Meningococcal disease. Chichester: John Wiley, 1995: 245–284.
11. Kristiansen BE, Ferm(beta)r C, Jenkins A, Ask E, Swedberg G, Skold O. PCR amplicon restriction endonuclease analysis of the chromosomal dhps gene of Neisseria meningitidis: a method for studying the spread of the disease-causing strain in contacts of patients with meningococcal disease. J Clin Microbiol 1995; 33: 1174–9.
12. Woods JP, Kersulyte D, Tolan RW, Berg CM, Berg DE. Use of arbitrarily primed polymerase chain reaction analysis to type disease and carrier strains of Neisseria meningitidis isolated during a university outbreak. J Infect Dis 1994; 169: 1384–9.